Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
ID: 357004Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Stimulating Hematology Investigation: New Endeavors (SHINE)" aimed at promoting innovative research in non-malignant hematology. This initiative invites investigator-initiated research project grant applications (R01) that focus on basic and early translational hematology research, with a particular emphasis on fostering diverse perspectives within research teams through a required Plan for Enhancing Diverse Perspectives (PEDP). Approximately $2.5 million is available for 5-8 awards, with applications due by February 5, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    Files
    Title
    Posted
    The National Institutes of Health (NIH) is issuing a Notice of Funding Opportunity (NOFO) titled "Stimulating Hematology Investigation: New Endeavors (SHINE)," promoting research in non-malignant hematology relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute on Aging, and the National Heart, Lung, and Blood Institute. This initiative invites investigator-initiated research project grant applications (R01) focusing on innovative areas within basic and early translational hematology research. Key components of the funding include the requirement for a Plan for Enhancing Diverse Perspectives (PEDP), aimed at fostering inclusivity within research teams. Approximately $2.5 million is allocated for 5-8 awards, with applications due by February 5, 2025, for new projects. Applicants must comply with specific registration processes, and proposals will be evaluated based on scientific merit, innovation, rigor, investigator expertise, and the effectiveness of diversity plans. The SHINE program's dynamic nature allows for evolving research topics, responding to emerging questions within the hematology field, guided by workshops and public meetings. Overall, this NOFO emphasizes NIH’s commitment to innovative research and inclusivity in the scientific community.
    Similar Opportunities
    Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Stimulating Hematology Investigation: New Endeavors (SHINE)" aimed at promoting innovative research in nonmalignant hematology. This program invites investigator-initiated R01 grant applications that focus on emerging topics such as blood cell development, the effects of aging on hematopoiesis, and metabolic influences on blood cell formation, with the goal of advancing the field of hematology. The total funding available for this initiative is approximately $2.15 million for fiscal year 2022, with an estimated 2-9 grants to be awarded, and applications must be submitted through Grants.gov by January 7, 2025. For further inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PAS-22-096.html.
    Notice of Intent to Publish a Funding Opportunity Announcement for Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the continuation of the NIDDK Hematology Central Coordinating Center (HCC) under a cooperative agreement. The HCC will collaborate with up to five Cooperative Centers of Excellence in Hematology (CCEH) to provide administrative support, develop communication strategies, and implement educational programs aimed at enhancing research in nonmalignant hematology. This initiative is crucial for fostering a national multidisciplinary research effort to study hematopoiesis and address nonmalignant hematologic diseases. The estimated total program funding is $1 million, with a single award anticipated, and the NOFO is expected to be published in December 2024, with applications due by March 2025. For further details, potential applicants should prepare to submit their proposals in alignment with the requirements outlined in the forthcoming NOFO.
    Limited Competition: Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Heart, Lung, and Blood Institute (NHLBI), has announced a Limited Competition Funding Opportunity titled "Physician Scientist Transition to Independence in Blood Science Research" (R00 - Clinical Trial Optional). This initiative aims to support the transition of outstanding blood science researchers with clinical doctorate degrees from mentored research positions to independent faculty roles, providing up to three years of funding for innovative research in blood science. The program is particularly focused on enhancing the scientific workforce by promoting diversity and fostering independent research careers that address critical health challenges in hematology. Interested applicants must submit their proposals by March 28, 2025, with a total funding ceiling of $250,000 available for new awards, and can direct inquiries to grantsinfo@nih.gov for further information.
    Investigator-Initiated Research in Genomics and Health Equity (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Investigator-Initiated Research in Genomics and Health Equity" (RFA-HG-23-017), aimed at promoting health equity through innovative genomic research. This initiative encourages applicants to propose research that enhances the understanding and application of genomics across diverse U.S. populations, with a particular focus on engaging underrepresented groups and incorporating a Plan for Enhancing Diverse Perspectives (PEDP). The NIH plans to commit significant funds, with a maximum budget of $500,000 in direct costs per year for projects lasting four to five years, and applications are due by July 8, 2025. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to review the full announcement at NIH Grants.
    Continuation of the NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the continuation of the NIDDK Hematology Central Coordinating Center (HCCC) through a cooperative agreement, aimed at enhancing collaboration among up to five Cooperative Centers of Excellence in Hematology. The HCCC will provide essential administrative and communication support, manage a Pilot and Feasibility Program, and promote research addressing nonmalignant hematologic diseases and normal hematopoiesis. This initiative is crucial for invigorating the field of hematology, fostering partnerships, and ensuring diverse perspectives in research teams. Interested applicants can find more information and apply by March 18, 2025, with an estimated funding amount of up to $1,000,000. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-25-023.html.
    Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Heart, Lung, and Blood Institute (NHLBI), is offering a federal grant opportunity titled "Short-Term Research Education Program to Enhance Diversity in Health-Related Research (R25 Clinical Trial Not Allowed)." This program aims to support educational activities that enhance the diversity of the biomedical, behavioral, and clinical research workforce by providing research experiences and related opportunities for individuals from underrepresented groups. The initiative is crucial for addressing health disparities in cardiovascular, pulmonary, and hematologic diseases by fostering a diverse scientific workforce. Interested applicants can apply for funding up to $175,000 per year for a maximum of five years, with applications opening on December 29, 2023, and a submission deadline of August 19, 2026. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-25-001.html.
    Advancing Genomic Medicine Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Advancing Genomic Medicine Research (R01 Clinical Trial Optional)" aimed at enhancing the use and sharing of genomic information in clinical care across diverse populations. This initiative seeks proposals that focus on understanding the implementation of genomic medicine, addressing barriers to access, and developing analytical tools for clinical genomic data, with a strong emphasis on inclusivity for populations experiencing health disparities. The NIH has allocated approximately $2.4 million for three projects, with an additional project funded by the National Cancer Institute, and applicants are required to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of their proposals. Interested parties must submit their applications by February 11, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Advancing Genomic Medicine Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting proposals for the "Advancing Genomic Medicine Research (R01 Clinical Trial Optional)" grant, aimed at stimulating innovative research in the implementation of genomic technologies in clinical care. This funding opportunity emphasizes addressing health disparities and requires applicants to develop a Plan for Enhancing Diverse Perspectives to ensure inclusivity in research teams and participant recruitment. The initiative seeks to explore the value of genomic data in improving clinical outcomes, identify barriers to implementation, and develop effective data-sharing methods, with approximately $2.4 million available for three awards and an additional $700,000 for one award in fiscal year 2024. Applications are due by February 12, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovation in the application of genomic information in clinical care, particularly for populations experiencing health disparities. The initiative seeks to enhance understanding of how to effectively implement and share genomic technologies across diverse communities, including racial and ethnic minorities, underserved rural populations, and sexual and gender minority groups. With an expected total funding of approximately $1.5 million for fiscal year 2024, individual project budgets may reach up to $250,000. Interested applicants must submit their proposals by February 11, 2025, and can find additional details and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Advancing Genomic Medicine Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Advancing Genomic Medicine Research (R21 Clinical Trial Optional)" aimed at stimulating innovative research in the integration of genomic information into clinical care, particularly for populations experiencing health disparities. This initiative encourages proposals that address implementation science, barriers to genomic medicine, and the integration of genomic data with health and social determinants, with a focus on enhancing health equity among underrepresented groups. The grant provides funding up to $250,000, with applications open from November 1, 2023, until the close date of February 11, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.